Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Probi AB (publ)
  6. News
  7. Summary
    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 08/04 11:29:52 am
465 SEK   -3.83%
07/16Probi Seeks Acquisitions
CI
07/16Q2 2021 : Probi enters new strategic partnerships
AQ
07/16Probi AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Probi : Improved probiotic products for women's health - an unmet market need

05/31/2021 | 06:01am EDT

Probi® enters into a probiotic research partnership with focus on vaginal health

Probi® and Tervisetehnoloogiate Arenduskeskus AS, Estonia, also known as the Competence Centre on Health Technologies (CCHT), have signed a long-term Research and Development collaboration agreement aimed to develop novel products based on probiotic lactobacilli strains. As part of the collaboration Probi will get specific access to a unique and proprietary bacterial strain library.

Professor Reet Mändar (CCHT and University of Tartu), who has longstanding expertise within this health area expresses her expectations to the research collaboration together with Probi: "We are hoping to introduce novel and scientifically validated probiotics with benefits for several gynecological disorders. I am looking forward to this highly synergistic cooperation with our scientific expertise in combination with Probi's skills in product development and commercialization."

Vaginal infections represent one of the most common reasons for gynecological consultations

70% of all women are estimated to experience at least one episode of yeast infection and 30% will suffer from bacterial vaginosis (inflammation caused by bacteria), among which many will have recurrent episodes12. Common for many vaginal infections is a disturbance of the vaginal microbiota where the normal protective lactobacilli dominated microbiota has been disrupted.

Titti Niskanen, Director R&D & Clinical Operations at Probi® comments: "Traditional treatment options have been centered around antibiotics and antifungals to get rid of the infection, but without focus on reestablishing a healthy balanced vaginal microbiota and in some cases causing an even more severe disruption. Thus, vaginal probiotics may have an important role in establishing healthy microbial communities in a natural way and thereby helping maintain vaginal health."

Hardi Tamm, Development manager at CCHT adds: "Probiotics have great potential to help reduce cases of recurrent infections, which sometimes can lead to more severe health conditions. Therefore, we are pleased to have reached a collaboration agreement with Probi and are looking forward to taking our existing know-how together to the next level in finding a health solution which meets the unmet needs of many women."

Efficacious and science supported probiotic vaginal health products - an unmet market need

There were 96 new vaginal health supplement launches in 2020 and 74 of these contained probiotics, corresponding to 77% of overall vaginal health supplement launches*. So, clearly the consumer need is there - and the belief that probiotics might play an important role is also there - but the question is if the current probiotic offerings meet the consumer expectations.

Tom Rönnlund, CEO, Probi: "Probiotics are well established as having health benefits within vaginal health, but there are ample opportunities for improved products on the market". And Rönnlund continues: "A long term collaboration with CCHT will add new expertise and opportunities into Probi's R&D portfolio and we are excited about the formation of this new relationship."

For further information, please contact:

Titti Niskanen, Director R&D & Clinical Operations, Probi®,
Phone: +46 46 286 89 68, E-mail: titti.niskanen@probi.com
Tom Rönnlund, CEO, Probi®,
Phone: +46 46 286 89 40, E-mail: trd@probi.com
Charlotte Beyerholm, Director Marketing & Global Communication, Probi®,
Phone: +46 76 870 94 65, E-mail: charlotte.beyerholm@probi.com
Hardi Tamm, Development manager, Tervisetehnoloogiate Arenduskeskus AS
Phone: +372 733 0401, E-mail: hardi.tamm@ccht.ee

 

References:

1 Yano, J. et al.(2019) BMC Women's Health 19 (48). https://doi.org/10.1186/s12905-019-0748-8
2 Peebles, K et al. (2019) Sexually Transmitted Diseases 46(5):304-311
*Innova Market Insights, November 2020 report from Innova Database

 

ABOUT PROBI

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process, and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical
documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to
more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com.

 

ABOUT THE COMPETENCE CENTRE ON HEALTH TECHNOLOGIES (CCHT)

Tervisetehnoloogiate Arenduskeskus AS (Competence Centre on Health Technologies, CCHT) is a biotechnology company focused on research and product development in personalised medicine, drug development and both human and veterinary reproductive medicine.  CCHT's core expertise lays in research-intensive analysis such as prenatal screening, endometrial receptivity testing etc. In order to develop innovative technologies it actively cooperates with many institutions in Europe and worldwide. Read more at www.ccht.ee.

https://news.cision.com/probi/r/improved-probiotic-products-for-women-s-health---an-unmet-market-need,c3353306

https://mb.cision.com/Main/1556/3353306/1424445.pdf

https://news.cision.com/probi/i/scientific-collaboration,c2918491

(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) -3.83% 465 Delayed Quote.14.57%
SYMRISE AG 0.16% 123.9 Delayed Quote.14.11%
All news about PROBI AB (PUBL)
07/16Probi Seeks Acquisitions
CI
07/16Q2 2021 : Probi enters new strategic partnerships
AQ
07/16Probi AB Publ Reports Earnings Results for the Second Quarter Ended June 30, ..
CI
07/13PROBI : Presentation of Probi's Q2 report 2021
PU
07/13PROBI : Presentation of Probi's Q2 report 2021
AQ
07/06PROBI : Snaps Up 13% Stake In Blis Technologies For $6 Million
MT
07/06PROBI : acquires newly issued shares in New Zealand's Blis...
PU
07/06Probi acquires newly issued shares in New Zealand's Blis Technologies and ent..
AQ
07/06Blis Technologies and Probi AB Signs a Licensing and Distribution Agreement
CI
06/15PROBI : and Oriflame enter partnership for digestive...
PU
More news
Financials
Sales 2021 712 M 82,7 M 82,7 M
Net income 2021 95,0 M 11,0 M 11,0 M
Net cash 2021 251 M 29,2 M 29,2 M
P/E ratio 2021 55,6x
Yield 2021 0,26%
Capitalization 5 298 M 615 M 616 M
EV / Sales 2021 7,09x
EV / Sales 2022 5,87x
Nbr of Employees -
Free-Float 36,6%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Last Close Price 465,00 SEK
Average target price 505,00 SEK
Spread / Average Target 8,60%
EPS Revisions
Managers and Directors
Tom Juhani R÷nnlund Chief Executive Officer
Henrik Lundkvist Chief Financial Officer
Jean-Yves Parisot Chairman
Niklas Brandt Vice President-Information Technology
Niklas Larsson Lead Scientific Affairs
Sector and Competitors
1st jan.Capi. (M$)
PROBI AB (PUBL)14.57%640
NESTLÉ S.A.9.44%346 893
MONDELEZ INTERNATIONAL, INC.8.40%88 594
YIHAI KERRY ARAWANA HOLDINGS CO., LTD-33.47%61 176
DANONE18.36%49 095
THE KRAFT HEINZ COMPANY12.35%47 629